Trials / Recruiting
RecruitingNCT07209410
Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma
Impact of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 35 (estimated)
- Sponsor
- Insight Eyecare Specialties, Inc. dba Vision Source Eyecare, · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the effect of brimonidine tartrate 0.025% on conjunctival hyperemia in patients treated with netarsudil 0.02%/latanoprost 0.005% mono-therapy for intraocular pressure lowering.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brimonidine Tartrate Ophthalmic 0.025% | Lumify is an approved eye drop to minimize ocular hyperemia. |
Timeline
- Start date
- 2025-11-01
- Primary completion
- 2026-12-15
- Completion
- 2027-06-01
- First posted
- 2025-10-07
- Last updated
- 2025-11-18
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07209410. Inclusion in this directory is not an endorsement.